In cirrhotic patients with variceal hemorrhage, treatment failure was 54.2% with desmopressin plus terlipressin versus 27.3% with terlipressin, p = 0.06.
In plain wordsIn cirrhotic patients with variceal bleeding, treatment failure was numerically higher after adding desmopressin to terlipressin.
- Peptide
- Desmopressin
- Outcome
- IncreaseTreatment failure
- Study
n = 46
- Comparator
- Placebo plus terlipressin
- Outcome group
- Bleeding Control · Gastrointestinal
- Studied dose
- 0.3 microgram/kg at time 0 and 26 hr · intravenousAs given in this study (human).
Measurements
- Treatment failures
- 13 patients
- desmopressin plus terlipressin
- Treatment failure rate
- 54.2%
- desmopressin plus terlipressin
- Treatment failures
- 6 patients
- terlipressin
- Treatment failure rate
- 27.3%
- terlipressin
- P value
- 0.06
- between groups
Source sentences
Treatment failure occurred in 13 of 24 patients randomized to receive desmopressin plus terlipressin (54.2%) and in 6 of 22 patients randomized to receive terlipressin (27.3%) (p = 0.06, Fisher's exact test).
2 context sentences(design, population, supporting numbers)
Cirrhotic patients with active variceal hemorrhage diagnosed endoscopically were randomized within 2 hr of admission to receive desmopressin plus terlipressin or placebo plus terlipressin.
Desmopressin (0.3 microgram/kg, intravenously) or placebo was given in saline solution over 30 min at time 0 and at 26 hr.